Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

PODD

Insulet Corporation

Sep 20 • 03:14PM ET

235.88

Dollar change -1.80
Percentage change -0.76	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO SPY IVV VB VO RSP XLV IHI VUG

Index	S&P 500	P/E	42.84	EPS (ttm)	5.51	Insider Own	0.67%	Shs Outstand	69.91M	Perf Week	0.86%
Market Cap	16.54B	Forward P/E	61.17	EPS next Y	3.86	Insider Trans	-6.55%	Shs Float	69.64M	Perf Month	26.96%
Income	395.30M	PEG	2.87	EPS next Q	0.79	Inst Own	100.66%	Short Float	4.19%	Perf Quarter	15.57%
Sales	1.87B	P/S	8.83	EPS this Y	2.24%	Inst Trans	-0.62%	Short Ratio	3.91	Perf Half Y	41.55%
Book/sh	14.24	P/B	16.56	EPS next Y	28.30%	ROA	15.01%	Short Interest	2.92M	Perf Year	43.18%
Cash/sh	11.71	P/C	20.15	EPS next 5Y	14.90%	ROE	50.93%	52W Range	125.82 - 243.98	Perf YTD	8.71%
Dividend Est.	-	P/FCF	86.60	EPS past 5Y	122.47%	ROI	16.76%	52W High	-3.32%	Beta	1.21
Dividend TTM	-	Quick Ratio	2.68	Sales past 5Y	24.75%	Gross Margin	69.59%	52W Low	87.48%	ATR (14)	7.86
Dividend Ex-Date	-	Current Ratio	3.56	EPS Y/Y TTM	525.48%	Oper. Margin	14.56%	RSI (14)	73.00	Volatility	2.81% 3.66%
Employees	3000	Debt/Eq	1.40	Sales Y/Y TTM	27.82%	Profit Margin	21.11%	Recom	1.52	Target Price	239.05
Option/Short	Yes / Yes	LT Debt/Eq	1.36	EPS Q/Q	565.31%	Payout	0.00%	Rel Volume	0.57	Prev Close	237.68
Sales Surprise	0.10%	EPS Surprise	359.46%	Sales Q/Q	23.20%	Earnings	Aug 08 AMC	Avg Volume	746.92K	Price	235.88
SMA20	10.04%	SMA50	16.66%	SMA200	23.70%	Trades		Volume	380,833	Change	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight	$235 → $340
Oct-18-22	Initiated	Barclays	Equal Weight	$238
Oct-12-22	Initiated	Jefferies	Hold	$260
Jul-11-22	Downgrade	Citigroup	Buy → Neutral	$310 → $250
Mar-02-22	Resumed	BofA Securities	Buy	$300
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy	$320
Feb-02-22	Upgrade	UBS	Neutral → Buy	$325
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform	$300 → $275
Jul-21-21	Resumed	Cowen	Outperform	$285 → $310
May-25-21	Initiated	Barclays	Overweight	$300
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$275 → $320

Show Previous Ratings

Sep-12-24 01:01PM	Insider Sale: Director Timothy Scannell Sells 5,000 Shares of Insulet Corp (PODD) (GuruFocus.com)
Sep-07-24 01:16AM	Insulets (PODD) Sales And Margins Surpassed Expectations (Insider Monkey)
Sep-05-24 07:22PM	Analyst Report: Insulet Corporation (Morningstar Research)
Sep-04-24 05:00PM	S&P 500 Gains and Losses Today: Dollar Tree Stock Tumbles After Earnings Miss (Investopedia)
Aug-30-24 10:35AM	Analyst Report: Insulet Corporation (Morningstar Research)
07:20AM	Loading…
07:20AM	Why Insulet Stock Was Zooming Higher This Week (Motley Fool)
01:46AM	Insider Sale at Insulet Corp (PODD): SVP & Chief Technology Officer Mark Field Sells Shares (GuruFocus.com)
Aug-28-24 05:25PM	S&P 500 Gains and Losses Today: Supermicro Stock Plunges on Annual Report Delay (Investopedia) +6.15%
Aug-27-24 05:36PM	S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index (Investopedia) +6.58%
12:48PM	Top Stock Movers Now: Nvidia, Insulet, Paramount Global, and More (Investopedia)
11:32AM	This Healthcare Stock Is the Best Performer in the S&P 500 After FDA Approval (Barrons.com)
10:08AM	Insulets Trang Ly on overcoming clinical inertia in diabetes care (MedTech Dive)
08:23AM	Insulet Omnipod cleared by FDA for type 2 diabetes (Medical Device Network)
Aug-26-24 04:20PM	Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes (Business Wire)
01:37PM	Insulet expands Omnipod 5 pump to people with Type 2 diabetes (MedTech Dive)
05:25PM	Loading…
Aug-20-24 05:25PM	S&P 500 Gains and Losses Today: Palo Alto Networks Surges After Earnings Beat (Investopedia) -6.87%
05:21PM	These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise (Investopedia)
12:11PM	Top Stock Movers Now: Boeing, Lowe's, Netflix, Eli Lilly, and More (Investopedia)
06:00AM	Insulet to Present at Upcoming Investor Conferences (Business Wire)
Aug-16-24 08:57PM	Insulet Corporation (PODD): This Diabetes Stock Is A Good Addition To Your Portfolio Now (Insider Monkey)
Aug-14-24 03:00AM	Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia (Business Wire)
Aug-10-24 01:04AM	Decoding Insulet Corp (PODD): A Strategic SWOT Insight (GuruFocus.com)
Aug-09-24 05:34PM	Analyst Report: Insulet Corporation (Morningstar Research) -8.81%
05:31PM	S&P 500 Gains and Losses Today: Expedia Soars as International Demand Drives Earnings Beat (Investopedia)
05:15PM	Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns (Investopedia)
01:19PM	Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Heres Why. (Barrons.com)
12:49PM	Top Stock Movers Now: Sweetgreen, Intel, Akamai Technologies, and More (Investopedia)
10:48AM	Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst (Benzinga)
09:24AM	Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised (Zacks)
Aug-08-24 08:07PM	Insulet inventory pressures cloud annual revenue forecast raise (Reuters)
05:30PM	Loading…
05:30PM	Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Insulet (PODD) Q2 Earnings Miss Estimates (Zacks)
04:07PM	Insulet: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year (Business Wire)
Aug-07-24 09:02AM	Earnings To Watch: Insulet Corp (PODD) Reports Q2 2024 Result (GuruFocus.com)
Aug-05-24 09:16AM	Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics (Zacks)
Aug-01-24 10:01AM	Insulet (PODD) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-26-24 09:37AM	Are Ozempic Jitters to Blame for DexCom's Stock-Price Plunge? (The Wall Street Journal)
06:00AM	Insulet Reports Preliminary Second Quarter 2024 Revenue Results (Business Wire)
Jul-18-24 12:00PM	All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy (Zacks)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire)
Jul-08-24 06:00AM	Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
Jun-25-24 02:32PM	Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 (Barrons.com)
Jun-24-24 04:08PM	Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks (Bloomberg)
08:36AM	Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes (Zacks)
08:13AM	Insulet seeks label expansion of Omnipod 5 for Type 2 diabetes (MedTech Dive)
07:13AM	Insulet plans label expansion for Omnipod in type 2 diabetes (Medical Device Network)
Jun-21-24 06:30PM	Insulets SECURE-T2D Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes (Business Wire)
10:59AM	Insulet (PODD) Faces Increasing Competition (Insider Monkey)
08:33AM	Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System (Zacks)
Jun-20-24 06:05AM	Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands (Business Wire)
06:00AM	Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates (Business Wire)
Jun-19-24 06:02AM	The 3 Best Diabetes Stocks to Buy in June 2024 (InvestorPlace)
Jun-17-24 07:01PM	Insider Sale at Insulet Corp (PODD) by SVP & Chief Technology Officer Mark Field (GuruFocus.com)
Jun-13-24 09:24AM	Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now? (Zacks)
Jun-11-24 07:00PM	Insider Sale: Director Timothy Scannell Sells 7,000 Shares of Insulet Corp (PODD) (GuruFocus.com)
Jun-06-24 06:19AM	7 Stocks That Could Safely 10X by 2030 (InvestorPlace)
May-30-24 09:59AM	PayPal upgraded, UiPath downgraded: Wall Street's top analyst calls (The Fly)
May-28-24 06:00AM	Insulet to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 09:50AM	Here's Why Insulet (PODD) is a Strong Momentum Stock (Zacks) -5.68%
May-22-24 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
May-19-24 02:08PM	Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains (InvestorPlace)
May-16-24 07:42AM	Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage (MedTech Dive)
May-14-24 04:47PM	S&P 500 Gains and Losses Today: Paramount Global Sinks as Sony Reconsiders Bid (Investopedia) +6.99%
04:44PM	Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market (Benzinga)
03:58PM	Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday? (Benzinga)
11:19AM	Insulet Shares Rise Despite Blue Orca's Short Position (MT Newswires)
May-13-24 10:48AM	Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised (Zacks)
May-10-24 04:55PM	S&P 500 Gains and Losses Today: Akamai Technologies Tumbles on Weak Guidance (Investopedia) -6.55%
03:25PM	Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:24PM	Insulet Corp (PODD) Reports Strong Q1 2024 Results and Raises Full-Year Guidance (GuruFocus.com)
09:43AM	Analyst Report: Insulet Corporation (Morningstar Research)
09:24AM	Raymond James Adjusts Price Target on Insulet to $213 From $218 (MT Newswires)
08:10AM	Wolfe Research Raises Price Target on Insulet to $205 From $200 (MT Newswires)
08:00AM	Canaccord Genuity Adjusts Price Target on Insulet to $234 From $226 (MT Newswires)
07:49AM	Jefferies Raises Price Target on Insulet to $260 From $255 (MT Newswires)
May-09-24 08:57PM	PODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:30PM	Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings (Zacks)
04:30PM	Insulet Q1 Earnings, Revenue Rise; 2024 Revenue Growth Boosted (MT Newswires)
04:11PM	Insulet: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year (Business Wire)
10:16AM	Nvidia, Micron and Super Micro among companies that shine in Wall Streets beat-and-raise game (MarketWatch)
May-07-24 06:00AM	Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth (Business Wire)
May-06-24 09:16AM	Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
May-02-24 06:15PM	Insulet (PODD) Rises Higher Than Market: Key Facts (Zacks)
09:50AM	Why Insulet (PODD) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-28-24 05:50PM	American Politicians are Selling These 10 Stocks (Insider Monkey)
Apr-26-24 06:15PM	Insulet (PODD) Outperforms Broader Market: What You Need to Know (Zacks)
Apr-24-24 08:42AM	Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect (Zacks)
Apr-15-24 09:45AM	7 Stable Stocks for 50% Returns by Early 2025 (InvestorPlace)
Apr-12-24 12:10PM	Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-10-24 06:15PM	Insulet (PODD) Stock Moves -0.34%: What You Should Know (Zacks)
Apr-03-24 06:00AM	Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-02-24 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
Mar-28-24 09:55AM	Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High? (Zacks)
Mar-26-24 05:10AM	32 Countries with the Highest Rates of Diabetes (Insider Monkey)
Mar-21-24 09:17AM	Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside (Barrons.com)
06:40AM	Insulet names Ana Maria Chadwick CFO (MedTech Dive)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
06:00AM	Insulet Appoints Ana Maria Chadwick as Chief Financial Officer (Business Wire)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopfield Jessica	Director	Sep 11 '24	Option Exercise	29.87	7,628	227,848	34,545	Sep 12 04:07 PM
Hopfield Jessica	Director	Sep 11 '24	Sale	225.26	7,628	1,718,283	26,917	Sep 12 04:07 PM
Scannell Timothy J	Director	Sep 10 '24	Sale	225.84	5,000	1,129,200	30,586	Sep 11 04:13 PM
Hopfield Jessica	Director	Sep 11 '24	Proposed Sale	225.26	7,628	1,718,283		Sep 11 03:40 PM
Field Mark N	SVP & Chief Technology Officer	Sep 09 '24	Sale	220.87	1,383	305,463	9,761	Sep 10 04:16 PM
Budden Lauren	Group VP, CAO and Controller	Sep 09 '24	Sale	221.41	1,506	333,443	6,609	Sep 10 04:15 PM
Scannell Timothy J	Director	Sep 10 '24	Proposed Sale	225.84	5,000	1,129,210		Sep 10 02:27 PM
Field Mark N	Officer	Sep 09 '24	Proposed Sale	220.87	1,383	305,465		Sep 09 04:50 PM
Budden Lauren	Officer	Sep 09 '24	Proposed Sale	221.41	1,506	333,436		Sep 09 01:20 PM
Singh Prem	SVP, Global Operations	Aug 30 '24	Sale	202.27	1,824	368,940	3,656	Sep 03 04:30 PM
Singh Prem	Officer	Aug 30 '24	Proposed Sale	202.27	1,824	368,938		Aug 30 03:22 PM
Chadwick Ana Maria	EVP, CFO & Treasurer	Aug 29 '24	Buy	206.00	100	20,600	13,314	Aug 29 04:17 PM
Field Mark N	SVP & Chief Technology Officer	Aug 28 '24	Sale	203.00	1,387	281,561	11,347	Aug 29 04:14 PM
Field Mark N	Officer	Aug 28 '24	Proposed Sale	203.00	1,387	281,561		Aug 28 04:02 PM
Field Mark N	SVP & Chief Technology Officer	Jun 14 '24	Sale	199.96	1,500	299,940	12,875	Jun 17 04:11 PM
Scannell Timothy J	Director	Jun 10 '24	Sale	190.51	7,000	1,333,570	35,586	Jun 11 04:12 PM
Field Mark N	SVP & Chief Technology Officer	Jun 10 '24	Sale	190.43	2,131	405,806	14,375	Jun 11 04:11 PM
BORIO LUCIANA	Director	Jun 04 '24	Sale	182.58	360	65,729	3,298	Jun 05 04:13 PM
Scannell Timothy J	Director	May 28 '24	Option Exercise	32.33	18,267	590,595	45,886	May 29 04:04 PM
Scannell Timothy J	Director	May 28 '24	Sale	180.90	3,300	596,970	42,586	May 29 04:04 PM
Petrovic Shacey	Director	Feb 28 '24	Option Exercise	92.11	11,609	1,069,305	14,176	Feb 29 04:37 PM
Petrovic Shacey	Director	Feb 28 '24	Sale	162.92	11,609	1,891,338	2,567	Feb 29 04:37 PM
BORIO LUCIANA	Director	Dec 15 '23	Sale	207.08	72	14,910	2,278	Dec 18 04:01 PM
Petrovic Shacey	Director	Nov 13 '23	Option Exercise	81.69	20,000	1,633,733	22,567	Nov 14 04:04 PM
Petrovic Shacey	Director	Nov 13 '23	Sale	164.33	20,000	3,286,600	2,567	Nov 14 04:04 PM
Petrovic Shacey	Director	Nov 13 '23	Sale	165.02	15,000	2,475,300	0	Nov 14 04:04 PM

Open in Screener

NVCR

NovoCure Ltd

Sep 20 • 03:14PM ET

17.50

Dollar change -0.34
Percentage change -1.90	%

Healthcare • Medical Devices • United Kingdom • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWO IBB IHI SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	9.89%	Shs Outstand	107.08M	Perf Week	-5.76%
Market Cap	1.89B	Forward P/E	-	EPS next Y	-1.48	Insider Trans	-0.03%	Shs Float	97.51M	Perf Month	0.01%
Income	-168.70M	PEG	-	EPS next Q	-0.33	Inst Own	85.85%	Short Float	6.39%	Perf Quarter	-8.23%
Sales	549.96M	P/S	3.44	EPS this Y	29.89%	Inst Trans	2.94%	Short Ratio	4.58	Perf Half Y	25.46%
Book/sh	3.35	P/B	5.23	EPS next Y	-8.57%	ROA	-14.23%	Short Interest	6.23M	Perf Year	-1.57%
Cash/sh	8.82	P/C	1.98	EPS next 5Y	-	ROE	-43.40%	52W Range	10.87 - 24.74	Perf YTD	17.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.97%	ROI	-16.27%	52W High	-29.25%	Beta	0.71
Dividend TTM	-	Quick Ratio	6.22	Sales past 5Y	17.16%	Gross Margin	75.96%	52W Low	61.00%	ATR (14)	1.14
Dividend Ex-Date	-	Current Ratio	6.46	EPS Y/Y TTM	4.62%	Oper. Margin	-32.06%	RSI (14)	46.82	Volatility	5.89% 6.70%
Employees	1453	Debt/Eq	1.87	Sales Y/Y TTM	8.33%	Profit Margin	-30.67%	Recom	2.14	Target Price	26.17
Option/Short	Yes / Yes	LT Debt/Eq	1.87	EPS Q/Q	42.63%	Payout	-	Rel Volume	0.37	Prev Close	17.84
Sales Surprise	10.70%	EPS Surprise	23.06%	Sales Q/Q	19.28%	Earnings	Jul 25 BMO	Avg Volume	1.36M	Price	17.50
SMA20	-1.82%	SMA50	-5.88%	SMA200	5.83%	Trades		Volume	445,757	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98
Jan-20-22	Upgrade	Truist	Hold → Buy	$125
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line	$82
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform	$159 → $154

Show Previous Ratings

Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)
Sep-06-24 05:19PM	Why NovoCure Stock Dived by 13% This Week (Motley Fool) -6.48%
Sep-03-24 07:00AM	Novocure Announces Planned CEO Transition (Business Wire) -13.84%
Aug-28-24 07:00AM	Novocure to Participate in 2024 Wells Fargo Healthcare Conference (Business Wire) +9.61%
Aug-16-24 09:55AM	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet (Zacks) -5.34%
07:00AM	Loading…
Aug-14-24 07:00AM	Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer (Business Wire)
Aug-12-24 03:59PM	Biotech stocks: Which drugmakers are worth a buy? (Yahoo Finance Video)
Jul-30-24 09:55AM	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade (Zacks) +12.24%
Jul-25-24 05:30PM	NovoCure (NVCR) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:11AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-16-24 08:45AM	CereVasc Announces Appointments of New Directors (PR Newswire) +7.17%
Jul-14-24 12:16PM	30 Wealthiest People in Switzerland (Insider Monkey)
Jul-01-24 07:00AM	Novocure to Report Second Quarter 2024 Financial Results (Business Wire)
10:44AM	Loading…
Jun-14-24 10:44AM	Cramer's Lightning Round: Novocure, PayPal, AeroVironment (CNBC TV)
Jun-03-24 08:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival (Business Wire) +8.54%
May-23-24 05:05PM	TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany (Business Wire) -5.86%
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace) +13.01%
May-10-24 05:14PM	Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.17%
May-03-24 12:08PM	NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:00AM	NovoCure (NVCR) Q1 2024 Earnings Call Transcript (Motley Fool)
May-02-24 01:19PM	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue (MT Newswires) +11.38%
11:56AM	NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:45AM	NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported (GuruFocus.com)
08:25AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:28AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon (Business Wire)
07:00AM	Novocure Reports First Quarter 2024 Financial Results (Business Wire)
Apr-25-24 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
10:45AM	Loading…
Apr-24-24 10:45AM	Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 (Business Wire)
Apr-05-24 07:00AM	Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 (Business Wire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade (Zacks)
07:00AM	Novocure to Report First Quarter 2024 Financial Results (Business Wire)
Mar-30-24 06:34AM	Why NovoCure Stock Soared 18.3% This Week (Motley Fool)
Mar-28-24 11:50AM	Why Novocure Stock Is Jumping Today (Motley Fool) +6.76%
05:01AM	NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 04:08PM	Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish (Investor's Business Daily) +12.01%
09:29AM	Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
09:16AM	Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment (Investor's Business Daily)
07:14AM	UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:12AM	Novocure's device shown to slow cancer progression in the brain in trial (Reuters)
07:05AM	Novocure's lung cancer therapy succeeds in late-stage trial (Reuters)
07:00AM	METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer (Business Wire)
Mar-13-24 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Business Wire)
Feb-23-24 11:43AM	NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 12:15PM	NovoCure (NVCR) Q4 2023 Earnings Call Transcript (Motley Fool)
08:25AM	NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:36AM	NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:23AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Business Wire)
Jan-19-24 07:46AM	Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength? (Zacks)
Jan-18-24 02:19PM	Why Is Cancer Focused Novocure Stock Trading Higher Today? (Benzinga) +16.75%
07:00AM	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Business Wire)
Jan-11-24 09:55AM	Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know (Zacks)
Jan-09-24 07:00AM	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Business Wire)
Jan-08-24 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Business Wire) +11.61%
Jan-04-24 04:05PM	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Business Wire)
Dec-27-23 07:00AM	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +12.20%
Dec-08-23 04:09AM	15 Best Falling Stocks To Buy Now (Insider Monkey)
Dec-04-23 04:46PM	The Top and Bottom Stocks of 2023 (Investopedia)
Nov-28-23 10:51AM	Novocure Layoffs 2023: What to Know About the Latest NVCR Job Cuts (InvestorPlace)
07:30AM	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Business Wire)
Nov-21-23 07:00AM	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-23 09:09AM	11 Best Undervalued UK Stocks To Buy Now (Insider Monkey) +12.48%
Nov-10-23 08:00AM	Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting (Business Wire)
Nov-03-23 06:45AM	Is Novocure Stock a Buy? (Motley Fool)
Oct-30-23 02:04AM	The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-28-23 08:39AM	NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 04:35PM	Why Novocure Stock Was Sick Today (Motley Fool) -7.53%
11:00AM	NovoCure (NVCR) Q3 2023 Earnings Call Transcript (Motley Fool)
08:52AM	NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:24AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-15-23 06:05PM	Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 (Business Wire)
Oct-12-23 08:00AM	Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program (Business Wire) -5.53%
Oct-02-23 07:00AM	Novocure to Report Third Quarter 2023 Financial Results (Business Wire)
Sep-29-23 05:00PM	Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting (Business Wire)
Sep-18-23 11:47AM	Should You Hold NovoCure Limited (NVCR)? (Insider Monkey)
Sep-08-23 04:01PM	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Business Wire)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Sep-04-23 09:30AM	Down 31% in 1 Day, What's Next for NovoCure Stock? (Motley Fool)
Aug-31-23 06:52PM	Why Novocure Stock Fell 24.4% This Week (Motley Fool)
09:55AM	Is NovoCure's Stock Headed for a Free Fall? (Motley Fool)
Aug-29-23 06:31PM	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Business Wire) +8.84% +8.30%
Aug-28-23 05:15PM	Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal (Investopedia) -37.50%
04:08PM	Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails (Investor's Business Daily)
02:19PM	Novocure Plummets 35% After Its Cancer Treatment Fails In Ovarian Cancer (Investor's Business Daily)
12:21PM	Why NovoCure Stock Is Crashing Today (Motley Fool)
12:16PM	3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023 (AP Finance)
12:10PM	NovoCure Ltd (NVCR): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:47AM	NovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth Exploration (GuruFocus.com)
09:34AM	Midday movers: 3M, XPeng, Hawaiian Electric Industries and more (Investing.com)
07:27AM	UPDATE 1-Novocure's cancer therapy fails to meet main goal in late-stage trial (Reuters)
07:10AM	Novocure says its ovarian cancer therapy did not meet main goal in late-stage trial (Reuters)
07:00AM	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Business Wire)
Aug-25-23 08:20AM	Could NovoCure Stock Help You Become a Millionaire? (Motley Fool)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Financial Officer	Aug 02 '24	Sale	20.14	688	13,857	219,179	Aug 05 04:25 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Jun 05 '24	Option Exercise	22.82	124,373	2,838,192	124,373	Jun 07 04:06 PM
VERNON W ANTHONY	Director	Jun 04 '24	Sale	23.89	964	23,033	164,833	Jun 06 05:43 PM
Scannell Timothy J	Director	Jun 04 '24	Sale	23.89	964	23,027	2,964	Jun 06 05:42 PM
LEUNG GABRIEL	Director	Jun 04 '24	Sale	23.89	964	23,025	78,175	Jun 06 05:42 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 01 '24	Sale	16.03	2,107	33,769	252,452	Mar 05 04:09 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 04 '24	Sale	16.01	1,217	19,484	251,235	Mar 05 04:09 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 01 '24	Sale	16.03	1,679	26,909	160,938	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 04 '24	Sale	16.01	840	13,448	160,098	Mar 05 04:08 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '24	Sale	16.14	2,078	33,545	162,617	Feb 29 04:38 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Feb 28 '24	Sale	16.14	2,303	37,177	254,559	Feb 29 04:28 PM
Shah Pritesh	Chief Growth Officer	Nov 07 '23	Sale	12.65	382	4,832	124,511	Nov 08 04:22 PM
Cordova Ashley	Chief Financial Officer	Oct 31 '23	Option Exercise	9.58	17,793	170,447	117,443	Nov 02 04:20 PM
Cordova Ashley	Chief Financial Officer	Nov 02 '23	Option Exercise	11.46	175	2,006	117,618	Nov 02 04:20 PM

PODD

Insulet Corporation

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience